{
    "deck": {
        "metadata": {
            "title": "ADC Clinical Insights Deck",
            "version": "1.0",
            "theme_key": "clinical_modern"
        },
        "slides": [
            {
                "slide_type": "meeting_info",
                "title": "MEETING INFORMARION",
                "body": [
                    {
                        "component": "text",
                        "content": "<ul>\n<li><strong>Event:</strong> Activeer\u00ae Nano Program: ADCs in the Treatment of HR+ mBC</li>\n<li><strong>Location:</strong> Virtual - Central</li>\n<li><strong>Date | Time:</strong> February 4 | 6:30 PM \u2013 8:30 PM CT</li>\n<li><strong>Moderator:</strong> Ruta Rao, MD</li>\n<li><strong>Attendees:</strong> 10 oncologists</li>\n</ul>"
                    },
                    [
                        {
                            "component": "table",
                            "content": "| Institution | # of Attendees |\n|-------------|----------------|\n| Advocate Lutheran General Hospital | 1 |\n| Beloit Clinic | 1 |\n| Highlands Oncology Group \\| Fayetteville | 1 |\n| Illinois Cancer Specialists | 1 |\n| Mercy Clinic \\| Saint Louis | 1 |\n| Northwest Cancer Center \\| Crown Point | 1 |\n| Oakland University William Beaumont School of Medicine | 1 |\n| Sanford Roger Maris Cancer Center | 1 |\n| Texas Oncology \\| Amarillo | 1 |\n| University of Texas Southwestern Medical Center \\| Dallas | 1 |"
                        },
                        {
                            "component": "map",
                            "content": [
                                "TX",
                                "WI",
                                "IL",
                                "MO",
                                "MI",
                                "IN",
                                "AR",
                                "ND"
                            ]
                        }
                    ]
                ]
            },
            {
                "slide_type": "content",
                "title": "Attendee Demographics",
                "body": [
                    {
                        "component": "chart",
                        "chartType": "horizontal_bar_chart",
                        "name": "Years Post-Residency Treating Patients With BC",
                        "bucket_label": "Years",
                        "count_label": "Physicians",
                        "aggregations": {
                            "0 to 3": 10,
                            "4 to 6": 0,
                            "7 to 10": 10,
                            "11 to 15": 30,
                            "16 to 20": 30,
                            "21 to 25": 0,
                            ">25": 20
                        }
                    },
                    {
                        "component": "chart",
                        "chartType": "horizontal_bar_chart",
                        "name": "Patient Location:",
                        "bucket_label": "Physicians",
                        "count_label": "Patients",
                        "aggregations": {
                            "1 to 5": 0,
                            "6 to 10": 40,
                            "11 to 20": 50,
                            "21 to 30": 30,
                            "31 to 50": 10,
                            ">50": 20
                        }
                    },
                    {
                        "component": "chart",
                        "chartType": "donut_chart",
                        "name": "Which 1L treatment would you now recommend for this patient with EGFR exon 19 del mNSCLC?",
                        "aggregations": {
                            "Osimertinib + chemotherapy": 44.4,
                            "Amivantamab SQ + lazertinib": 33.3,
                            "Osimertinib monotherapy": 22.2
                        }
                    }
                ]
            }
        ]
    }
}